ENvue Medical

Company Overview

Snapshot

Founded in December 2003, ENvue Medical operates with 11–50 employees and has raised a total of $24.5 million across 9 funding rounds from 1 investor. The company went public on NASDAQ in April 2014, marking a significant milestone in its journey to redefine clinical navigation.

Business overview

ENvue Medical is a Health Tech & Life Sciences company focused on redefining clinical navigation through its Enhanced Navigation platform. The company's core technology supports critical medical procedures such as enteral feeding and vascular access, aiming to reduce complications, accelerate training, and improve efficiency. ENvue Medical serves the healthcare industry by providing advanced tools that enhance patient care and enable hospitals and clinicians to achieve optimal outcomes.

Strategic signal

In May 2026, ENvue Medical secured a three-year purchasing agreement renewal with a major U.S. health system, operating over 90 hospitals, and also received a USPTO Notice of Allowance for its ultrasound-enhanced cannabinoid drug delivery technology. These developments signal strong market adoption and continued innovation, reinforcing the company's strategic position in medical navigation and therapeutic delivery.

Company Intelligence Q&A

What was a recent significant intellectual property development for ENvue Medical?

In May 2026, ENvue Medical added to its intellectual property portfolio by securing a USPTO Notice of Allowance for its ultrasound-enhanced cannabinoid drug delivery technology.

Did ENvue Medical recently renew any major purchasing agreements?

Yes, in May 2026, ENvue Medical secured a three-year purchasing agreement renewal with the Group Purchasing Organization (GPO) for one of the largest health systems in the U.S., which operates over 90 hospitals.

What was a key strategic move for ENvue Medical in February 2025?

In February 2025, ENvue Medical acquired Envizion Medical, expanding its capabilities and market presence in medical navigation technologies.

What was a significant product adoption milestone for ENvue Medical in May 2025?

In May 2025, a major Louisiana hospital selected the ENvue System for feeding tube procedures, indicating growing adoption of the company's navigation platform.

What was the outcome of NanoVibronix's registered direct offering in September 2025?

In September 2025, NanoVibronix announced the pricing of a $2.0 million registered direct offering priced at-the-market under Nasdaq Rules.